“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Former a16z partner Vijay Pande has launched VZVC, an AI-focused venture firm that emphasizes a more selective investment strategy compared to his previous management of a multi-billion dollar biotech portfolio. Pande intends to concentrate on fewer companies to better support the integration of AI into biological research. This transition reflects a broader shift in the sector toward viewing biology as an engineering discipline, though Pande notes that high costs for clinical trials remain a significant barrier to progress.